Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy

Area of Science:

• Biochemistry and Molecular Biology
• Medicinal Chemistry
• Oncology

Background:

• Targeted protein degradation is a key strategy for addressing challenging therapeutic targets.
• Proteolysis-targeting chimeras (PROTACs) leverage the ubiquitin-proteasome system for selective protein degradation.
• PROTACs show promise in cancer therapy, particularly for "undruggable" targets, but face limitations like poor solubility and off-target toxicity.

Purpose of the Study:

• To summarize novel, unconventional Proteolysis-targeting chimera (PROTAC) designs.
• To address the limitations of conventional PROTACs for improved therapeutic efficacy.
• To explore new directions for PROTAC-based drug development in cancer therapy.

Main Methods:

• Review and categorization of four types of unconventional PROTACs.
• Analysis of PROTACs featuring unconventional binding ligands.
• Examination of PROTACs with modified linker designs, pro-PROTACs, and self-assembled PROTACs.

Main Results:

• Unconventional PROTAC designs effectively address limitations such as poor solubility, permeability, the hook effect, and off-target toxicity.
• These optimized PROTACs enhance the efficacy of cancer therapy.
• The reviewed designs pave the way for PROTAC-based universal platforms.

Conclusions:

• Structural innovations in PROTACs are crucial for realizing their full therapeutic potential.
• Unconventional PROTACs offer promising avenues for overcoming existing challenges in drug development.
• These advancements expand the application scope of PROTACs in targeted cancer therapy.